Pancreatic Ductal Adenocarcinoma (mPDAC)
Oncology
1
Pipeline Programs
2
Companies
2
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2025
2026
2027
2028
2029
RegeneronCemiplimab Plus Gemcitabine
ExThera MedicalONCObind
Clinical Trials (2)
Total enrollment: 163 patients across 2 trials
Cemiplimab Plus Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma
Start: Jan 2026Est. completion: Dec 202943 patients
Phase 2Recruiting
OSCAR II STUDY - The ONCObind CTC Removal Study
Start: Oct 2025Est. completion: Jun 2026120 patients
N/ANot Yet Recruiting
Related Jobs in Oncology
Senior Research Associate, Immuno-Oncology
SystImmune
5m ago
$60K - $85K/yr
Research Associate I/II, Immuno-Oncology
SystImmune
5m ago
Office Administrator
SystImmune
6m ago
$60K - $80K/yr
Scientist/Sr Scientist
TwoStep Therapeutics
San Carlos
16m ago
Working Student Office Management Support (m/f/d)
Mindpeak
Hamburg
20m ago
Senior Medical Project Manager (m/f/d)
Mindpeak
Hamburg
20m ago
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 163 patients
2 companies competing in this space